A specialized menopause and metabolic consultation may help determine whether additional metabolic options may be appropriate as part of your care plan
Weight-Related Outcomes At week 26, the estimated mean change from baseline in body weight was 8.6% with the 12-mg dose of orforglipron, 11.2% with the 24-mg dose, 12.3% with the 36-mg dose, 12.6% with the 45-mg dose, and 2.0% with placebo
Enhanced Aesthetics & Wellnesss Role Enhanced Aesthetics & Wellness plays a vital role in administering Semaglutide treatments
BPC-157 has shown interactions with vagal signaling in animal models, though the specifics of this interaction are still being characterized
Retatrutide 40mg is a double-concentration formulation of LY-3437943 supplied in Alluvi Healthcares pre-filled sealed research pen
Tirzepatide ODT contains the same active ingredient as injectable tirzepatide and is expected to share a similar side effect profile, though this formulation has not undergone clinical trials